When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Prion disease

Last reviewed: 1 Oct 2025
Last updated: 27 Sep 2024

Summary

定义

病史和体格检查

关键诊断因素

  • cognitive impairment
  • limb and/or gait ataxia
  • myoclonus
  • parkinsonism
  • psychiatric symptoms
  • visual changes
  • age late 20s or mid-to-late 60s
  • insomnia, dysautonomia
  • positive family history
  • nonspecific or constitutional symptoms
完整详情

其他诊断因素

  • painful sensory symptoms
  • movement disorder
完整详情

危险因素

  • genetic predisposition
  • prion-contaminated surgical instruments
  • transfusion of blood or blood products (variant Creutzfeldt-Jakob disease)
  • consumption of UK beef from 1980 to 1996
  • consumption of US beef
  • deer, elk, moose hunting in endemic regions of US and Canada
  • use of human growth hormone
完整详情

诊断性检查

首要检查

  • brain MRI
  • EEG
完整详情

需考虑的检查

  • quaking-induced conversion (QuIC)
  • CSF biomarkers
  • prion protein gene genetic testing
  • biopsy (brain, tonsil)
完整详情

治疗流程

持续性治疗

all patients

撰稿人

作者

Valerie Sim, MD, FRCPC

Associate Professor

Department of Medicine

Division of Neurology

Centre for Prions and Protein Folding Diseases

University of Alberta

Edmonton

Alberta

Canada

利益声明

VS is principal and co-investigator on several research grants through the University of Alberta, to study prion disease and related neurodegenerative diseases. VS has one patent approved for the development of IgE-based prion therapy. VS is currently a site lead for the Ionis PrProfile trial. VS has been invited to give an educational session on prion disease at the American Academy of Neurology meeting in 2024.

鸣谢

Dr Valerie Sim would like to gratefully acknowledge Dr Michael D. Geschwind, Dr Amy Kuo, and Dr R. Ronald Finley, the previous contributors to this topic. MDG participates in the speakers' bureau for Pfizer, Forest, and Novartis; is consultant for MedaCorp, Gerson-Lehman Group, and Clinical Advisors Incorporated; and is an author of a number of references cited in this topic. RRF participates in the speakers' bureau for Pfizer, Forest, and Novartis. AK declares that she has no competing interests.

同行评议者

Ali Hassoun, MD, FACP, FIDSA, AAHIVS

Infectious Disease Specialist

Alabama Infectious Diseases Center

Huntsville

AL

利益声明

AH declares that he has no competing interests.

Robert A. Larsen, MD

Associate Professor of Medicine

University of Southern California

Keck School of Medicine

Los Angeles

CA

利益声明

RAL declares that he has no competing interests.

William A. Petri, Jr., MD, PhD, FACP

Chief and Professor of Medicine

Division of Infectious Diseases and International Health

University of Virginia Health System

Charlottesville

VA

利益声明

WAP declares that he has no competing interests.

Peer reviewer acknowledgements

BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.

Disclosures

Peer reviewer affiliations and disclosures pertain to the time of the review.

参考文献

Our in-house evidence and editorial teams collaborate with international expert contributors and peer reviewers to ensure that we provide access to the most clinically relevant information possible.

关键文献

Department of Health. Minimise transmission risk of CJD and vCJD in healthcare settings. Nov 2021 [internet publication].全文

Centers for Disease Control and Prevention. BSE (Bovine spongiform encephalopathy, or mad cow disease). Sep 2021 [internet publication].全文

American College of Radiology. ACR appropriateness criteria: movement disorders and neurodegenerative diseases. 2019 [internet publication].全文

参考文献

A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.
  • Prion disease images
  • 鉴别诊断

    • Alzheimer dementia (AD)
    • Lewy body dementia
    • Frontotemporal dementia
    更多 鉴别诊断
  • 指南

    • ACR appropriateness criteria: movement disorders and neurodegenerative diseases
    • Evidence-based guideline: diagnostic accuracy of CSF 14-3-3 protein in sporadic Creutzfeldt-Jakob disease
    更多 指南
  • padlock-locked登录或订阅即可浏览 BMJ Best Practice 临床实践完整内容

内容使用需遵循免责声明